Literature DB >> 16269471

Adjuvant trastuzumab for breast cancer.

Rebecca Dent, Mark Clemons.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16269471      PMCID: PMC1283169          DOI: 10.1136/bmj.331.7524.1035

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Trastuzumab in the treatment of breast cancer.

Authors:  Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

4.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

6.  Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.

Authors:  J D Sato; T Kawamoto; A D Le; J Mendelsohn; J Polikoff; G H Sato
Journal:  Mol Biol Med       Date:  1983-12
  6 in total
  10 in total

1.  Adjuvant trastuzumab for breast cancer: the other side of the coin.

Authors:  Somasundari Gopalakrishnan; John Linnane
Journal:  BMJ       Date:  2005-11-19

2.  Adjuvant trastuzumab for breast cancer: an increasingly common ethical and economic conundrum.

Authors:  Matthew L Grove
Journal:  BMJ       Date:  2005-11-19

3.  Adjuvant trastuzumab for breast cancer: editorial does not mention health economics of drug.

Authors:  E Hamish McLaren
Journal:  BMJ       Date:  2005-11-19

4.  Adjuvant trastuzumab for breast cancer: advent of pharmacogenetics raises many issues.

Authors:  Hazel Thornton
Journal:  BMJ       Date:  2005-11-19

Review 5.  How much will Herceptin really cost?

Authors:  Ann Barrett; Tom Roques; Matthew Small; Richard D Smith
Journal:  BMJ       Date:  2006-11-25

6.  Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment.

Authors:  Malcolm R Kell; Colm P Power
Journal:  BMJ       Date:  2005-11-19

7.  HER2 testing in the UK: consensus from a national consultation.

Authors:  Mitch Dowsett; A M Hanby; R Laing; R Walker
Journal:  J Clin Pathol       Date:  2007-02-23       Impact factor: 3.411

8.  Media influence on Herceptin subsidization in Australia: application of the rule of rescue?

Authors:  Ross Mackenzie; Simon Chapman; Glenn Salkeld; Simon Holding
Journal:  J R Soc Med       Date:  2008-06       Impact factor: 5.344

Review 9.  HER2 status in breast cancer--an example of pharmacogenetic testing.

Authors:  Mark Kroese; Ron L Zimmern; Sarah E Pinder
Journal:  J R Soc Med       Date:  2007-07       Impact factor: 5.344

Review 10.  Current controversies in the management of early breast cancer.

Authors:  L G Estévez; M Martín; E Alba; R Colomer; F Lobo; A Lluch; E Adrover; J Albanell; A Barnadas; J García-Mata; A Llombart; M Muñoz; C Rodríguez; P Sánchez-Rovira; M A Seguí; I Tusquets
Journal:  Clin Transl Oncol       Date:  2007-06       Impact factor: 3.340

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.